Patent expiration to drive biosimilars market expansion to 2032
European Pharmaceutical Review
APRIL 11, 2024
Expirations of biologic patents has enabled manufacturers to enter the market and offer lower-cost alternatives of these drugs, according to the report. This has resulted in “increased competition and price pressure, driving the growth of the biosimilar market”. million by 2032, at 17.6 percent CAGR between 2023 and 2032.
Let's personalize your content